Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Using Standard Transducers Versus Simulines Transducers
Status: Enrolling
Updated:  2/20/2018
Wilmington Dermatology Center
mi
from
Wilmington, NC
Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers
Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Using Standard Transducers Versus Simulines Transducers
Status: Enrolling
Updated: 2/20/2018
Wilmington Dermatology Center
mi
from
Wilmington, NC
Click here to add this to my saved trials
Retinol-induced Dermatitis in Aged Skin
Molecular Analyses of Retinoid-induced Dermatitis in Aged/Photoaged Human Skin
Status: Enrolling
Updated:  2/20/2018
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Retinol-induced Dermatitis in Aged Skin
Molecular Analyses of Retinoid-induced Dermatitis in Aged/Photoaged Human Skin
Status: Enrolling
Updated: 2/20/2018
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated:  2/21/2018
International Dermatology Research, Inc.
mi
from
Miami, FL
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated: 2/21/2018
International Dermatology Research, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated:  2/21/2018
Summit Dermatology
mi
from
Oakbrook Terrace, IL
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated: 2/21/2018
Summit Dermatology
mi
from
Oakbrook Terrace, IL
Click here to add this to my saved trials
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated:  2/21/2018
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated: 2/21/2018
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated:  2/21/2018
Mount Sinai St. Luke's
mi
from
New York, NY
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Status: Enrolling
Updated: 2/21/2018
Mount Sinai St. Luke's
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers
Status: Enrolling
Updated:  2/21/2018
Clinical Research Solutions
mi
from
Franklin, TN
A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers
Status: Enrolling
Updated: 2/21/2018
Clinical Research Solutions
mi
from
Franklin, TN
Click here to add this to my saved trials
Cultural Differences in Treatment Preferences and Perceptions of Acne
Cultural, Racial, and Ethnic Differences in Treatment Preferences and Perceptions of Acne Vulgaris
Status: Enrolling
Updated:  3/2/2018
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Cultural Differences in Treatment Preferences and Perceptions of Acne
Cultural, Racial, and Ethnic Differences in Treatment Preferences and Perceptions of Acne Vulgaris
Status: Enrolling
Updated: 3/2/2018
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
Status: Enrolling
Updated:  3/5/2018
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
Status: Enrolling
Updated: 3/5/2018
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/5/2018
University of Colorado Hospital
mi
from
Denver, CO
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/5/2018
University of Colorado Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated:  3/6/2018
Tower Outpatient Surgery Center--Dr. Joel Aronowitz
mi
from
Los Angeles, CA
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated: 3/6/2018
Tower Outpatient Surgery Center--Dr. Joel Aronowitz
mi
from
Los Angeles, CA
Click here to add this to my saved trials
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated:  3/6/2018
Foundation For Hair Restoration
mi
from
Miami, FL
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated: 3/6/2018
Foundation For Hair Restoration
mi
from
Miami, FL
Click here to add this to my saved trials
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated:  3/6/2018
Glasgold Surgery Group
mi
from
Highland Park, NJ
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated: 3/6/2018
Glasgold Surgery Group
mi
from
Highland Park, NJ
Click here to add this to my saved trials
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated:  3/6/2018
Laser and Skin Surgery Center of New York
mi
from
New York, NY
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial
Status: Enrolling
Updated: 3/6/2018
Laser and Skin Surgery Center of New York
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo
Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo
Status: Enrolling
Updated:  3/9/2018
Johns Hopkins Dept. of Dermatology
mi
from
Baltimore, MD
Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo
Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo
Status: Enrolling
Updated: 3/9/2018
Johns Hopkins Dept. of Dermatology
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Comparative Study of Occlusive Heat Patch in the Treatment of Warts
A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca
Status: Enrolling
Updated:  3/13/2018
Yale School of Medicine
mi
from
New Haven, CT
A Comparative Study of Occlusive Heat Patch in the Treatment of Warts
A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca
Status: Enrolling
Updated: 3/13/2018
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
NECCR Primacare Research, LLC
mi
from
Fall River, MA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
NECCR Primacare Research, LLC
mi
from
Fall River, MA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Main Road Family Medicine
mi
from
South Westport, MA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Main Road Family Medicine
mi
from
South Westport, MA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Essentia Institute of Rural Health
mi
from
Duluth, MN
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Essentia Institute of Rural Health
mi
from
Duluth, MN
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Harleysville Medical Associates
mi
from
Harleysville, PA
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Harleysville Medical Associates
mi
from
Harleysville, PA
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Lincoln Primary Care
mi
from
Lincoln, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Lincoln Primary Care
mi
from
Lincoln, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Miriam Hospital
mi
from
Providence, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Center for Medical Research LLC
mi
from
Providence, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Center for Medical Research LLC
mi
from
Providence, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Ocean State Primary Care
mi
from
Westerly, RI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Ocean State Primary Care
mi
from
Westerly, RI
Click here to add this to my saved trials
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated:  3/16/2018
Marshfield Clinic Research Institute
mi
from
Marshfield, WI
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
Status: Enrolling
Updated: 3/16/2018
Marshfield Clinic Research Institute
mi
from
Marshfield, WI
Click here to add this to my saved trials
Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy
Randomized Double Blind Study Comparing Liquid Nitrogen Cryotherapy With Nd:YAG in the Treatment of Verruca Vulgaris
Status: Enrolling
Updated:  3/20/2018
St Joseph Mercy Hospital
mi
from
Ypsilanti, MI
Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy
Randomized Double Blind Study Comparing Liquid Nitrogen Cryotherapy With Nd:YAG in the Treatment of Verruca Vulgaris
Status: Enrolling
Updated: 3/20/2018
St Joseph Mercy Hospital
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy and Asthma Relief Experts
mi
from
Granada Hills, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy and Asthma Relief Experts
mi
from
Granada Hills, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy & Asthma Care Center of Southern California
mi
from
Long Beach, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy & Asthma Care Center of Southern California
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Dermatology Research Associate
mi
from
Los Angeles, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Dermatology Research Associate
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Southern California Research Center
mi
from
Mission Viejo, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Southern California Research Center
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Choc Psf, Amc
mi
from
Orange, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Choc Psf, Amc
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy & Asthma Consultants
mi
from
Redwood City, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy & Asthma Consultants
mi
from
Redwood City, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy & Asthma Clinical Research, Inc.
mi
from
Walnut Creek, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy & Asthma Clinical Research, Inc.
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Colorado Allergy and Asthma Centers, PC
mi
from
Denver, CO
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Colorado Allergy and Asthma Centers, PC
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Florida Center for Allergy & Asthma Research
mi
from
Aventura, FL
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Florida Center for Allergy & Asthma Research
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Florida Ctr-Allergy & Asthma
mi
from
Miami, FL
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Florida Ctr-Allergy & Asthma
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Sarasota Clinical Research
mi
from
Sarasota, FL
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Sarasota Clinical Research
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
University of South Florida
mi
from
Tampa, FL
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Clinical Research Center of Southern Illinois LLC
mi
from
Shiloh, IL
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Clinical Research Center of Southern Illinois LLC
mi
from
Shiloh, IL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Deaconess Clinic, Inc.
mi
from
Evansville, IN
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Deaconess Clinic, Inc.
mi
from
Evansville, IN
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Dawes Fretzin Clinical Res LLC
mi
from
Indianapolis, IN
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Dawes Fretzin Clinical Res LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Abraham Research, PLLC
mi
from
Fort Mitchell, KY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Abraham Research, PLLC
mi
from
Fort Mitchell, KY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Dermatology Specialists Research
mi
from
Louisville, KY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Dermatology Specialists Research
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy & Asthma Specialists, PSC
mi
from
Owensboro, KY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy & Asthma Specialists, PSC
mi
from
Owensboro, KY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Asthma, Allergy & Sinus Center
mi
from
Baltimore, MD
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Asthma, Allergy & Sinus Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Respiratory Medicine Research; Institue of Michigan P.L.C.
mi
from
Ypsilanti, MI
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Respiratory Medicine Research; Institue of Michigan P.L.C.
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
James Q Del Rosso, DO, LLC
mi
from
Las Vegas, NV
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
James Q Del Rosso, DO, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials